Zobrazeno 1 - 10
of 197
pro vyhledávání: '"pegcetacoplan"'
Autor:
M. V. Marchenko, O. U. Klimova, E. V. Anikina, A. V. Lapina, T. A. Rudakova, T. I. Ksenzova, A. D. Kulagin
Publikováno v:
Онкогематология, Vol 19, Iss 3, Pp 68-78 (2024)
The introduction of the complement component C5 inhibitor eculizumab has radically changed the prognosis and quality of life of patients with paroxysmal nocturnal hemoglobinuria. Up to 30 % of patients develop only a suboptimal response to C5 inhibit
Externí odkaz:
https://doaj.org/article/71420cfe4cba44df9b8161e886d0f53e
Autor:
Di Matteo S, Freilone R, Bruno GM, Notaro R, Moumene S, Martone N, Teruzzi C, Ciccarone A, Colombo GL
Publikováno v:
ClinicoEconomics and Outcomes Research, Vol Volume 16, Pp 225-232 (2024)
Sergio Di Matteo,1 Roberto Freilone,2 Giacomo Matteo Bruno,1,3 Rosario Notaro,4 Sabrin Moumene,1 Nicoletta Martone,5 Cristina Teruzzi,5 Antonio Ciccarone,1 Giorgio Lorenzo Colombo1,3 1Center of Research, SAVE Studi - Health Economics and Outcomes Res
Externí odkaz:
https://doaj.org/article/4629608afc194b81af209a6a659bb5e2
Autor:
V. D. Latyshev, Z. T. Fidarova, R. V. Ponomarev, N. V. Tsvetaeva, E. A. Mikhaylova, E. A. Lukina, E. N. Parovichnikova
Publikováno v:
Онкогематология, Vol 19, Iss 1, Pp 83-91 (2024)
Background. Paroxysmal nocturnal hemoglobinuria is a rare clonal disease of the hematopoietic system, with the key manifestations of hemolytic anemia, a high thrombosis rate, and bone marrow failure. Despite the high efficacy of C5‑inhibitors in in
Externí odkaz:
https://doaj.org/article/719811036e4c4f839846b9282e0ac275
Autor:
Yara Maria da Silva Pires, Aline de Fátima Bonetti, Jessica Telma Ciecilinsky, Astrid Wiens Souza
Publikováno v:
Clinical Immunology Communications, Vol 3, Iss , Pp 37-41 (2023)
Paroxysmal nocturnal hemoglobinuria (PNH) is a non-malignant clonal disorder of the pluripotent hematopoietic stem cell. Currently, Eculizumab, Ravulizumab, and Pegcetacoplan are the approved drugs to treat PNH. In order to assess the efficacy and sa
Externí odkaz:
https://doaj.org/article/4894484c192d488388ae83c7c43540e1
Publikováno v:
American Journal of Ophthalmology Case Reports, Vol 33, Iss , Pp 101999- (2024)
Purpose: To describe a case of retinal vaso-occlusive vasculitis with associated lid edema and conjunctivitis following intravitreal pegcetacoplan administration in a patient with geographic atrophy (GA). Observation: A 78 year old Caucasian woman pr
Externí odkaz:
https://doaj.org/article/e395d72b8e87490ca4c99c9959c8e6db
Publikováno v:
International Journal of Retina and Vitreous, Vol 10, Iss 1, Pp 1-3 (2024)
Abstract Intravitreal injections are a common procedure in ophthalmology, often using syringes coated with silicone to aid piston movement and needles coated with silicone oil to facilitate penetration of the sclera. Pegcetacoplan and avacincaptad pe
Externí odkaz:
https://doaj.org/article/1cfb9928733e40d4a44d7479c7e66241
Publikováno v:
International Journal of Retina and Vitreous, Vol 9, Iss 1, Pp 1-3 (2023)
Abstract The approval of Syfovre® (pegcetacoplan) and Iverzay® (avacincaptad pegol) for the treatment of geographic atrophy (GA) marks a significant advancement in retinal disease therapy, offering both complement 3 and complement 5 inhibitors. Wit
Externí odkaz:
https://doaj.org/article/26dee2747eb943fb96541d15a29494e3
Publikováno v:
International Journal of Retina and Vitreous, Vol 9, Iss 1, Pp 1-12 (2023)
Abstract Geographic atrophy (GA) is a progressive degenerative disease that significantly contributes to visual impairment in individuals aged 50 years and older. The development of GA is influenced by various modifiable and non-modifiable risk facto
Externí odkaz:
https://doaj.org/article/09113a114b214ea389e5e497abfac144
Publikováno v:
Hematology Reports, Vol 15, Iss 4, Pp 578-591 (2023)
European Society for Blood and Marrow Transplantation (EBMT) hematologic response categories comprehensively assess complement inhibitor responses in patients with paroxysmal nocturnal hemoglobinuria (PNH). Using data from the 16-week randomized cont
Externí odkaz:
https://doaj.org/article/fce0e3528a4c4be388e607a378d91875
Autor:
Dun Jack Fu, Veronika Lipkova, Bart Liefers, Sophie Glinton, Livia Faes, Alex McKeown, Lukas Scheibler, Nikolas Pontikos, Praveen J. Patel, Gongyu Zhang, Pearse A. Keane, Konstantinos Balaskas
Publikováno v:
Ophthalmology and Therapy, Vol 12, Iss 6, Pp 3143-3158 (2023)
Abstract Introduction To evaluate the effect pegcetacoplan, a C3 and C3b inhibitor, on the rate of progression of geographic atrophy (GA) as assessed by spectral domain optical coherence tomography (SD-OCT) using a split-person study design and deep-
Externí odkaz:
https://doaj.org/article/f5f43e69d85a499a9b021ce09e606f78